About A/Prof Nada Hamad

A/Prof Nada Hamad is a staff specialist BMT, clinical and laboratory haematologist at St Vincent’s hospital in Sydney, chair of the ACI NSW BMT network, past EviQ haematology reference committee chair and senior lecturer at the University of Sydney and University of NSW. A/Prof Hamad studied Medicine at the University of Sydney and completed her Haematology training in Sydney. Prior to her career in medicine, she completed a Bachelor of Science and Master of Science in Forensics, working in this field for a short period of time. She completed two post-graduate fellowships in BMT and lymphoma at the Princess Margaret Cancer Centre in Toronto Canada through the University of Toronto. She has a strong interest in clinical trials, has a specialist certificate in Clinical Research (Oncology) from the University of Melbourne and is an active member of the Australasian Leukaemia and Lymphoma Group (ALLG) as a member of a number of disease group committees. Her BMT clinical research interests are in graft versus host disease and long term follow up post BMT.

Bulletin #1 : Practical suggestions for BMT programmes dealing with COVID-19

There is emerging evidence that COVID-19 severity and mortality is higher in patients with cancer (1, 2). In the likely scenario of community spread of COVID-19 in Australia and New Zealand, BMT programmes need to consider ways to reduce risks to patients and staff. The intention of this document is to summarise recommendations from national and international sources for BMT programmes, and to compile suggestions from the ANZ BMT community for local practices. Heads of BMT programmes in the region have reviewed and contributed to the suggestions below.

To date, recommendations have been circulated from WBMT, WMDA, EBMT and ABMDR regarding donors and recipients of HPC. These are summarised in the Table. The WMDA share site (share.wmda.info) has the most detailed information regarding donors and impact on registry operations.

Download the COVID19 Bulletin #1